Revenue and profit after tax declined year-over-year and sequentially in Q1 FY25, with EBITDA and margins also lower. Only the bulk drug and chemicals segment is reported, and the financials passed a limited review with no material misstatements.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.